<h3>复活节促销 - TipRanks 70% 折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>锦欣生殖集团有限公司（(HK:1951)）已分享最新动态。</p>
<p>锦欣生殖集团有限公司已取消了在 2024 年和 2025 年根据一般授权回购的 52,662,000 股股份，减少其总发行股本从 2,757,706,043 股降至 2,705,044,043 股。董事会预计取消这些回购股份将提升净资产价值和每股收益，并计划在 2026 年继续采用类似的回购取消和注销方式，表明持续关注股东价值。</p>
<p>此举突显了公司在生育和生殖医疗服务提供商竞争中寻求市场差异化的资本管理策略。通过缩减股份基础，锦欣生殖旨在增强其财务指标，并可能提高其对投资者的吸引力，同时保留在未来回购时重复此类取消的灵活性。</p>
<p>（HK:1951）股票的最新分析师评级为持有，目标价为 HK$2.50。要查看锦欣生殖集团有限公司股票的完整分析师预测列表，请参见 HK:1951 股票预测页面。</p>
<p><strong>关于锦欣生殖集团有限公司的更多信息</strong></p>
<p>锦欣生殖集团有限公司是一家注册于开曼群岛的公司，上市于香港，专注于生育和辅助生殖服务领域。该集团致力于为生育患者提供医疗治疗和相关服务，定位于中国及更广泛的亚洲日益增长的生殖医疗市场。</p>
<p><strong>平均交易量：</strong> 22,615,482</p>
<p><strong>技术情绪信号：</strong> 持有</p>
<p><strong>当前市值：</strong> HK$6.86B</p>

标普生物技术 3 倍做多 - Direxion

招商中证生物科技主题ETF

<p>锦欣生殖集团有限公司已取消 5270 万股回购股份，减少其总发行股本至 27 亿股。此举旨在提升净资产价值和每股收益，反映公司对股东价值的承诺。公司计划在未来的回购中继续这一策略。目前，该股票维持持有评级，目标价为 2.50 港元。锦欣专注于生育和辅助生殖服务领域，致力于亚洲日益增长的生殖医疗市场</p>

<h3>Easter Sale - 70% Off TipRanks</h3>
<div class="lb-trans"><h3>复活节促销 - TipRanks 70% 折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级为市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>Jinxin Fertility Group Ltd. ( (HK:1951) ) has shared an update.</p>
<div class="lb-trans"><p>锦欣生殖集团有限公司（(HK:1951)）已分享最新动态。</p>
</div><p>Jinxin Fertility Group Limited has cancelled 52,662,000 shares that it previously repurchased under general mandates granted in 2024 and 2025, reducing its total issued share capital from 2,757,706,043 to 2,705,044,043 shares. The board expects the cancellation of these repurchased shares to enhance net asset value and earnings per share and plans to continue using a similar cancel-and-retire approach for buybacks during 2026, signaling an ongoing focus on shareholder value.</p>
<div class="lb-trans"><p>锦欣生殖集团有限公司已取消了在 2024 年和 2025 年根据一般授权回购的 52,662,000 股股份，减少其总发行股本从 2,757,706,043 股降至 2,705,044,043 股。董事会预计取消这些回购股份将提升净资产价值和每股收益，并计划在 2026 年继续采用类似的回购取消和注销方式，表明持续关注股东价值。</p>
</div><p>The move underscores the company’s capital management strategy at a time when fertility and reproductive healthcare providers are competing to differentiate themselves in the market. By shrinking the share base, Jinxin Fertility aims to strengthen its financial metrics and potentially improve its appeal to investors, while retaining flexibility to repeat such cancellations as future repurchases are executed.</p>
<div class="lb-trans"><p>此举突显了公司在生育和生殖医疗服务提供商竞争中寻求市场差异化的资本管理策略。通过缩减股份基础，锦欣生殖旨在增强其财务指标，并可能提高其对投资者的吸引力，同时保留在未来回购时重复此类取消的灵活性。</p>
</div><p>The most recent analyst rating on (HK:1951) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Jinxin Fertility Group Ltd. stock, see the HK:1951 Stock Forecast page.</p>
<div class="lb-trans"><p>（HK:1951）股票的最新分析师评级为持有，目标价为 HK$2.50。要查看锦欣生殖集团有限公司股票的完整分析师预测列表，请参见 HK:1951 股票预测页面。</p>
</div><p><strong>More about Jinxin Fertility Group Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于锦欣生殖集团有限公司的更多信息</strong></p>
</div><p>Jinxin Fertility Group Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates in the fertility and assisted reproductive services sector. The group focuses on providing medical treatments and related services for fertility patients, positioning itself within the growing reproductive healthcare market in China and broader Asia.</p>
<div class="lb-trans"><p>锦欣生殖集团有限公司是一家注册于开曼群岛的公司，上市于香港，专注于生育和辅助生殖服务领域。该集团致力于为生育患者提供医疗治疗和相关服务，定位于中国及更广泛的亚洲日益增长的生殖医疗市场。</p>
</div><p><strong>Average Trading Volume:</strong> 22,615,482</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 22,615,482</p>
</div><p><strong>Technical Sentiment Signal:</strong> Hold</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 持有</p>
</div><p><strong>Current Market Cap:</strong> HK$6.86B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> HK$6.86B</p>
</div>

锦欣生殖取消了 5270 万回购股份，以提升每股财务指标